This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.

We have delivered strong operational performance over the last three years and are positioned to maintain the momentum. The executives highlighted five assets that are growth drivers in major therapeutic areas, as well as five mid-to-late stage assets in Oncology and six mid-to-late stage assets in Pharmaceuticals with key milestones expected in 2021 and 2022.

We are also taking significant steps to …

  • Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies
  • Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future sales expansion
  • Advancing leading pipeline based on scale, …

At age 14, Gisela Delgado felt unwell. She thought she had the flu, but when she noticed blood in her urine, she rushed to the emergency room.1

Six months later, in 1994, she was diagnosed with IgA nephropathy (IgAN), a kidney disease in which the body’s immune system attacks and slowly destroys the kidneys. There were no approved therapies for the disease. In the coming years, Delgado would lose weight and energy, and her quality of life would decline. Within 25 years, her doctors told her, her kidneys would probably fail. 

“It was my first year of high school. I …

  • Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indications
  • Addition of remestemcel-L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-based technology with platform potential
  • Deal includes $50 million upfront …

Before leaving port, sailors rely on meteorological data – wind force, swell, air temperature – to help them predict weather conditions at sea and stay safe.

Drug developers at Novartis are also using data to take a look into the future. They are working with the company Cibiltech to forecast disease progression of transplant patients with the help of a computer algorithm.

With this digital tool, the team at Novartis aims to reduce the time it takes to prove that an experimental therapy is safe and effective.

The partnership is part of a larger strategy at Novartis to …

  • Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs
  • ELARA results for Kymriah® in relapsed or refractory (r/r) follicular lymphoma, plus long-term JULIET data on response survival and durability at more than three years in r/r DLBCL patients
  • Detailed Jakavi

Photovoltaic power plant in Egypt - Photo credit / copyright: ACCIONA

Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve …

  • Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid

  • Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1

  • Agreements mark a major milestone on the Novartis environmental sustainability journey to be carbon neutral …

Novartis scientist Leila Haery likes to step away from the lab and wander in nature for perspective. While outdoors, the gene therapy expert contemplates the vastness of landscapes and their evolution over time. She’s inspired to ask new questions with the potential to shape an emerging field of medicine.

Leila’s story is the first in Making Possible, a video series about lives that have been touched by cell and gene therapy. Researchers share what it’s like to work toward …

People crossing the street in Cape Town

Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …